Drug developer Cennerv makes second bid to list on Catalist

Singapore

SINGAPORE-based biotech Cennerv Pharmaceuticals is making a second attempt at an initial public offering (IPO) on the Singapore Exchange's Catalist board, with the lodging of another preliminary offer document on Wednesday. Details of the pricing, amount to be raised, and timing of the offer have yet to be announced.

The firm, which develops drugs to treat central nervous system disorders, first registered a preliminary offer document for a planned listing in September last year. Asked why this was subsequently withdrawn, the company said: "Due to adverse market conditions in the last quarter of 2018, the company decided not to proceed with a listing in 2018."